---
trial_id: 295
discovery_date: 2022-03-30 22:57:49.243365
date: 2022-03-30 22:57:49.243365
title: "Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVAÂ® (efalizumab) in the framework of..."
summary: |
  <p>EudraCT Number: 2007-001377-28<br />Sponsor Protocol Number: 27577<br />Sponsor Name: Merck Serono International S.A.<br />Start Date: 2008-06-11<br />Medical condition: Adult patients with moderate to severe chronic plaque psoriasis 
  -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10061664<br />Term: Autoimmune disorder<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10025139<br />Term: Lupus erythematosus systemic<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10047888<br />Term: Wegener's granulomatosis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10002817<br />Term: Antiphospholipid syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10040767<br />Term: Sjogren's syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10039073<br />Term: Rheumatoid arthritis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10045228<br />Term: Type I diabetes mellitus<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10011401<br />Term: Crohn's disease<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10009900<br />Term: Colitis ulcerative<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10003827<br />Term: Autoimmune hepatitis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10049046<br />Term: Autoimmune thyroiditis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10003822<br />Term: Autoimmune haemolytic anaemia NOS<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10034697<br />Term: Pernicious anemia<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028417<br />Term: Myasthenia gravis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10018620<br />Term: Goodpasture's syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10018766<br />Term: Guillain Barre syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10043554<br />Term: Thrombocytopenia<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10037153<br />Term: Psoriasis<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/FR">FR</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/DE">DE</a> (Prematurely Ended), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/AT">AT</a> (Prematurely Ended), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/NL">NL</a> (Prematurely Ended), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/PT">PT</a> (Prematurely Ended)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-001377-28'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2007-001377-28<br />Sponsor Protocol Number: 27577<br />Sponsor Name: Merck Serono International S.A.<br />Start Date: 2008-06-11<br />Medical condition: Adult patients with moderate to severe chronic plaque psoriasis 
-- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10061664<br />Term: Autoimmune disorder<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10025139<br />Term: Lupus erythematosus systemic<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10047888<br />Term: Wegener's granulomatosis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10002817<br />Term: Antiphospholipid syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10040767<br />Term: Sjogren's syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10039073<br />Term: Rheumatoid arthritis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10045228<br />Term: Type I diabetes mellitus<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10011401<br />Term: Crohn's disease<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10009900<br />Term: Colitis ulcerative<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10003827<br />Term: Autoimmune hepatitis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10049046<br />Term: Autoimmune thyroiditis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10003822<br />Term: Autoimmune haemolytic anaemia NOS<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10034697<br />Term: Pernicious anemia<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028417<br />Term: Myasthenia gravis<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10018620<br />Term: Goodpasture's syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10018766<br />Term: Guillain Barre syndrome<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10043554<br />Term: Thrombocytopenia<br />Level: LLT<br />Version: 9.1<br />SOC Term: <br />Classification Code: 10037153<br />Term: Psoriasis<br />Level: LLT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/FR">FR</a> (Completed), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/DE">DE</a> (Prematurely Ended), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/AT">AT</a> (Prematurely Ended), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/NL">NL</a> (Prematurely Ended), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001377-28/PT">PT</a> (Prematurely Ended)</p>